# 6. Bölüm

# KARDİYAK İSKEMİ REPERFÜZYON

Ülkü SABUNCU[1]
Işın GÜNEŞ[2]

## 6. 1. MİYOKARD İSKEMİ REPERFÜZYON HASARI

Kalbe gelen kan akımının kesilmesi ya da azalması sonucu miyokardın oksijen sunum ve tüketim dengesi bozulur ve bunun sonucunda miyokard iskemisi meydana gelir. Takibinde kan akımının çeşitli tekniklerle restorasyonu miyokardda gelişen hasarı azaltır ancak reperfüzyon olarak tanımlanan bu süreç yine miyokard hasarına neden olabilir. Bu durum miyokard iskemi reperfüzyon (İ/R) hasarı olarak tanımlanmıştır. Miyokard İ/R hasarı miyokard iskemisi, kardiyak arrest ve kardiyak cerrahiyi takiben olumsuz sonuçlara neden olmaktadır (1).

## 6.2. KARDİYAK ANATOMİ ve FİZYOLOJİ

Kalp toraks boşluğundaki 3 kaviteden biri olan perikardiyal kavitenin içinde, 2. ve 5. interkostal mesafe arasında yer alır. Bu kavite koni şeklindedir, kalbin tamamını ve büyük damarların proksimal kısımlarını barındırır (2,3). İki atriyum ve 2 ventrikülden oluşur. Diğer organ ve dokularımızın perfüzyonunu sağlamak için 7/24 kan pompalarken bu esnada kendi perfüzyonunu da sağlar. Kalp her defasında kanı sağ ve sol pulmoner arterler ile pulmoner dolaşıma, aort ile sistemik dolaşıma pompalar. Atriyumlar özelleşmiş iletim sistemini içerirken, kalbin uyarılarını başlatan başlangıç pompası gibi görev yapar, ventriküller ise, asıl pompa görevini yapar (2,3).

1 Uzm. Dr., Tepecik Eğitim Araştırma Hastanesi, Algoloji Bilim Dalı, sabuncuulku@gmail.com
2 Doç. Dr., Erciyes Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon AD., isingunes@yahoo.com

## Kaynaklar

1. Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth 2012;16(3):123-32.
2. Frank H. Nettter. The Netter Collection Of Medical İllustrations, Volume 5: Heart Bölüm 1, Anatomy 2007:2-33.
3. Pollock JD, Makaryus AN. Physiology, Cardiac Cycle. 2020 Oct 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29083687.
4. Strobeck JE, Sonnenblick EH. Myocardial and ventricular function. Part II: Intact heart. Herz 1981;6(5):275-87.
5. Little RC, Little WC. Cardiac preload, afterload, and heart failure. Arch Intern Med 1982;142(4):819-22.
6. John F. Butterworth, David C. Mackey, John D. Wasnick, Morgan and Mikhail's Clinical Anesthesiology, Chapter 20: Cardiovascular Physiology and Anesthesia; McGraw Hill Medical Books. 6th edition,2018.
7. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils--a key component of ischemia-reperfusion injury. Shock 2013;40(6):463-70.
8. Muir WW, Hamlin RL. Myocardial Contractility: Historical and Contemporary Considerations. Front Physiol 2020;11:222. doi: 10.3389/fphys.2020.00222.
9. Maxwell JT, Blatter LA. A novel mechanism of tandem activation of ryanodine receptors by cytosolic and SR luminal $Ca^{2+}$ during excitation-contraction coupling in atrial myocytes. J Physiol 2017;595(12):3835-45.
10. Saxton A, Tariq MA, Bordoni B. Anatomy, Thorax, Cardiac Muscle. 2021 Feb 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30570976.
11. Eisner DA, Caldwell JL, Kistamás K, Trafford AW. Calcium and Excitation-Contraction Coupling in the Heart. Circ Res 2017;121(2):181-95.
12. Feher J. The Cardiac Action Potential. In Quantitative Human Physiology. Elsevier, 2012;458-66.
13. Pinnell J, Turner S, Howell S. Cardiac muscle physiology, Continuing Education in Anaesthesia Critical Care & Pain 2007;7(3):85–8.
14. Higgins CB, Vatner SF, Braunwald E. Parasympathetic control of the heart. Pharmacol Rev 1973;25(1):119-55.
15. JP Howard Fee, James G Bovill, Physiology for Anesthesiologist, Part 1: Cardiovascular Physiology. Taylor and Francis Group, United Kingdom. 2004:1-33.
16. Leslie RA, Johnson EK, Goodwin AP. (Eds.). Dr Podcast Scripts for the Primary FRCA. Chapter 1.2. Cardiovascular Physiology. Cambridge University Press. 2011:30-52.
17. Rehman S, Khan A, Rehman A. Physiology, Coronary Circulation. [Updated 2020 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK482413.
18. Bassenge E, Heusch G. Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 1990;116:77-165.
19. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454-71.
20. Kumar V, Abbas AK, Aster JC. (2017). Robbins basic pathology e-book. Chapter 11 Heart. Elsevier Health Sciences.2017:399-441.
21. Halladin NL. Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries. Dan Med J 2015;62(4):B5054.
22. Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med 2011;17(11):1391-401.

23. Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol 2019;136:27-41.
24. Liu XM, Yang ZM, Liu XK. Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model. Eur Rev Med Pharmacol Sci 2017;21(12):2913-18.
25. Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med 2018;117:76-89.
26. Zhou T, Chuang CC, Zuo L. Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion Injury. Biomed Res Int 2015;2015:864946. doi: 10.1155/2015/864946.
27. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005;100(2):179-90.
28. Agrawal V, Gupta JK, Qureshi SS, Vishwakarma VK. Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart. Indian Heart J 2016;68(6):856-61.
29. Escobales N, Nuñez RE, Javadov S. Mitochondrial angiotensin receptors and cardioprotective pathways. Am J Physiol Heart Circ Physiol 2019;316(6):H1426-38.
30. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61(3):481-97.
31. Schanze N, Bode C, Duerschmied D. Platelet Contributions to Myocardial Ischemia/Reperfusion Injury. Front Immunol 2019;10:1260. doi: 10.3389/fimmu.2019.01260.
32. Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res 1993;72(6):1181-90.
33. Yang BC, Mehta JL. Platelet-derived adenosine contributes to the cardioprotective effects of platelets against ischemia-reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 1994;24(5):779-85.
34. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124-36.
35. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation 1999;100(5):559-63.
36. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation 1991;84(1):341-9.
37. Downey JM, Cohen MV. Mechanisms of preconditioning: correlates and epiphenomena. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: BIOS Scientific Publishers Limited. 1996:21-34.
38. Yellon DM, Baxter GF. A “second window of protection” or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 1995;27(4):1023-34.
39. Auchampach JA, Gross GJ. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993;264(5 Pt 2):H1327-36.
40. Yao Z, Mizumura T, Mei DA, Gross GJ. KATP channels and memory of ischemic preconditioning in dogs: synergism between adenosine and KATP channels. Am J Physiol 1997;272(1 Pt 2):H334-42.
41. Sengul İ, Sengul D. Place of Mitochondrial Potassium-ATP Channels in The Mechanism of Effect of Ischemic Conditionings. J Clin Anal Med 2012;3(3): 370-3.
42. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285(2):H579-88.
43. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111(2):194-7.
44. Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 2005;289(1):H2-7.

45. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62(1):74-85.
46. Sun HY, Wang NP, Kerendi F, Halkos M, Kin H, Guyton RA, et al. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol 2005;288(4):H1900-8.
47. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95(3):230-2.
48. Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, et al. Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones. Cardiovasc Res 2012;95(4):487-94.
49. Donato M, Buchholz B, Rodríguez M, Pérez V, Inserte J, García-Dorado D, et al. Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol 2013;98(2):425-34.
50. Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol 2016;111(4):50. doi: 10.1007/s00395-016-0568-z.
51. Basalay MV, Mastitskaya S, Mrochek A, Ackland GL, Del Arroyo AG, Sanchez J, et al. Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. Cardiovasc Res 2016;112(3):669-76.
52. Bosnjak ZJ, Ge ZD. The application of remote ischemic conditioning in cardiac surgery. F1000Res 2017;6:928. doi: 10.12688/f1000research.11018.1.
53. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010;105(5):657-64.
54. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 2013;382(9892):597-604.
55. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, et al. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 2013;6(3):246-51.
56. Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 2009;119(6):820-7.
57. Heusch G, Gersh BJ. ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! Eur Heart J 2016;37(2):200-2.
58. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001;94(6):1133-8.
59. Canbaz S, Duran E, Ege T, Sunar H, Cikirikcioglu M, Acipayam M. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery. Thorac Cardiovasc Surg 2003;51(2):57-61.
60. Lassnigg A, Punz A, Barker R, Keznickl P, Manhart N, Roth E, et al. Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 2003;90(2):148-54.
61. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 2003;41(5):699-705.

62. González-Montero J, Brito R, Gajardo AI, Rodrigo R. Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities. World J Cardiol 2018;10(9):74-86.
63. Wang X, Yang L, Kang L, Li J, Yang L, Zhang J, et al. Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes. PLoS One 2017;12(8):e0182777. doi: 10.1371/journal.pone.0182777.
64. Liang S, Ping Z, Ge J. Coenzyme Q10 Regulates Antioxidative Stress and Autophagy in Acute Myocardial Ischemia-Reperfusion Injury. Oxid Med Cell Longev 2017;2017:9863181. doi: 10.1155/2017/9863181.
65. Wang W, Kang PM. Oxidative Stress and Antioxidant Treatments in Cardiovascular Diseases. Antioxidants (Basel) 2020;9(12):1292. doi: 10.3390/antiox9121292.
66. Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie 2015;61(2-3):77-84.
67. Sun H, Gusdon AM, Qu S. Effects of melatonin on cardiovascular diseases: progress in the past year. Curr Opin Lipidol 2016;27(4):408-13.
68. Carreira RS, Monteiro P, Gon Alves LM, Providência LA. Carvedilol: just another Beta-blocker or a powerful cardioprotector? Cardiovasc Hematol Disord Drug Targets 2006;6(4):257-66.
69. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007;25(4):731-41.
70. Li XS, Uriuda Y, Wang QD, Norlander R, Sjöquist PO, Pernow J. Role of L-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart. Acta Physiol Scand 1996;156(1):37-44.
71. Pernow J, Bohm F, Beltran E, Gonon A. L-arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo. J Appl Physiol (1985) 2003;95(6):2218-22.
72. Moens A. Claeys M. Bosmans J. Herman A. VC. Folate improves endothelial function after ischemia/reperfusion. Circulation 2002; 106 (Ref Type: Abstract): II-297.
73. Moens A, Claeys M, Bosmans J, Timmermans JP, Vrints C. Pretreatment with folic acid prevents ischemia/reperfusion induced endothelial dysfunction. J Am Coll Cardiol 2003;41(6):330A.
74. Sack S, Mohri M, Schwarz ER, Arras M, Schaper J, Ballagi-Pordány G, et al. Effects of a new Na+/H+ antiporter inhibitor on postischemic reperfusion in pig heart. J Cardiovasc Pharmacol 1994;23(1):72-8.
75. Xue YX, Aye NN, Hashimoto K. Antiarrhythmic effects of HOE642, a novel Na(+)-H+ exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol 1996;317(2-3):309-16.
76. Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, et al; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 2003;126(2):420-7.
77. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ Physiol 2002;283(1):H29-37.
78. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85(3):893-904.
79. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34(6):1711-20.
80. Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalán R, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998;98(21):2227-34.
81. Li H, Wang C, Sun J, Liu C, Li N, Chen J. Pravastatin Decreases Infarct Size Induced by Coronary Artery Ischemia/Reperfusion with Elevated eNOS Expression in Rats. Int Heart J 2018;59(1):154-60.

82. Abarbanell AM, Herrmann JL, Weil BR, Wang Y, Tan J, Moberly SP, et al. Animal models of myocardial and vascular injury. J Surg Res 2010;162(2):239-49.
83. Verdouw PD, van den Doel MA, de Zeeuw S, Duncker DJ. Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res 1998;39(1):121-35.
84. Ytrehus K. The ischemic heart--experimental models. Pharmacol Res 2000;42(3):193-203.
85. Chorro FJ, Such-Belenguer L, López-Merino V. Modelos animales de enfermedad cardiovascular [Animal models of cardiovascular disease]. Rev Esp Cardiol 2009;62(1):69-84.
86. Zornoff LA, Paiva SA, Minicucci MF, Spadaro J. Experimental myocardium infarction in rats: analysis of the model. Arq Bras Cardiol 2009;93(4):434-40, 426-32.
87. Ytrehus K. Models of myocardial ischemia. Drug Discovery Today: Disease Models 2006;3(3):263-71.
88. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006;30(2):353-61.
89. Lv X, Lu P, Hu Y, Xu T. miR-346 Inhibited Apoptosis Against Myocardial Ischemia-Reperfusion Injury via Targeting Bax in Rats. Drug Des Devel Ther 2020;14:895-905.
90. Litwin SE. The rat model of postinfarction heart failure. Heart Fail 1995;11:182-95.
91. Wu Y, Yin X, Wijaya C, Huang MH, McConnell BK. Acute myocardial infarction in rats. J Vis Exp 2011;(48):2464. doi: 10.3791/2464.
92. Liu P, Xu B, Cavalieri TA, Hock CE. Age-related difference in myocardial function and inflammation in a rat model of myocardial ischemia-reperfusion. Cardiovasc Res 2002;56(3):443-53.
93. Conci E, Pachinger O, Metzler B. Mouse models for myocardial ischaemia/reperfusion Journal Für Kardiologie - Austrian Journal of Cardiology 2006;13(7-8):239-44.
94. Camacho P, Fan H, Liu Z, He JQ. Large Mammalian Animal Models of Heart Disease. J Cardiovasc Dev Dis 2016;3(4):30. doi: 10.3390/jcdd3040030.
95. Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990;66(4):1133-42.
96. Chen Y, Shao DB, Zhang FX, Zhang J, Yuan W, Man YL, et al. Establishment and evaluation of a swine model of acute myocardial infarction and reperfusion-ventricular fibrillation-cardiac arrest using the interventional technique. J Chin Med Assoc 2013;76(9):491-6.
97. Crisóstomo V, Maestre J, Maynar M, Sun F, Báez-Díaz C, Usón J, et al. Development of a closed chest model of chronic myocardial infarction in Swine: magnetic resonance imaging and pathological evaluation. ISRN Cardiol 2013;2013:781762. doi: 10.1155/2013/781762.
98. Suzuki Y, Lyons JK, Yeung AC, Ikeno F. In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc Interv 2008;71(1):100-7.
99. Jones SP, Tang XL, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC, et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res 2015;116(4):572-86.
100. Sharp TE 3rd, Gong Z, Scarborough A, Goetzman ES, Ali MJ, Spaletra P, et al. Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury. JACC Basic Transl Sci 2020;5(7):699-714.
101. Duan T, Song R, Zhang J, Kong R, Lei H, Xiang D. Continuous balloon occlusion has more influence on microcirculation function assessed by the index of coronary microcirculatory resistance in a pig model. Int J Clin Exp Med 2018;11(12):13003-13.
102. Lindsey ML, Bolli R, Canty JM Jr, Du XJ, Frangogiannis NG, Frantz S, et al. Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol 2018;314(4):H812-38.